Jim Cramer Boosts Sellas Shares Leading to 7% Rally Ahead of Phase 3 AML Data
SLS•Sellas Life Sciences shares rose 2% overnight and climbed 7% Thursday, marking their fourth straight session in the green and best month of 2026 after Jim Cramer gave the stock 'two thumbs up.' Investors await final analysis of the Phase 3 Regal trial, now at 78 of 80 events.
1. Jim Cramer Endorsement Spurs Rally
Shares of Sellas Life Sciences climbed 2% in overnight trading and jumped 7% on Thursday, marking a fourth straight positive session and best monthly performance of 2026 after Jim Cramer gave the stock a bullish 'two thumbs up' endorsement. This momentum extends a five-week rally that has drawn heightened investor interest.
2. Phase 3 Regal Trial Nears Readout
The Phase 3 Regal trial of galinpepimut-S (GPS) in acute myeloid leukemia patients who have achieved remission but are not eligible for stem cell transplant has reached 78 of the 80 events needed for final analysis. Reaching this threshold signals that topline results are imminent, potentially validating GPS efficacy in targeting the WT1 cancer antigen.
3. SLS009 Data Looms as Next Catalyst
Sellas’ second AML candidate, SLS009, remains on the radar with topline data expected later this year. Investors view both GPS and SLS009 readouts as key catalysts that will inform the company’s clinical trajectory and valuation prospects.
